A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis

Raed Alroughani, Dirk Deleu, Khalid El Salem, Jasem Al-Hashel, K. John Alexander, Mohamed Assem Abdelrazek, Adel Aljishi, Jaber Alkhaboori, Faisal Al Azri, Nahida Al Zadjali, Majed Hbahbih, Tag Eldin Sokrab, Mohamed Said, Àlex Rovira

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course of the disease at a rate greater than the general population. Brain volume loss (BVL) is associated with disability progression and cognitive impairment in patients with MS; hence its value as a potential target in monitoring and treating MS is discussed. Methods: A group of MS neurologists and neuro-radiologists reviewed the current literature on brain atrophy and discussed the challenges in assessing and implementing brain atrophy measurements in clinical practice. The panel used a voting system to reach a consensus and the votes were counted for the proposed set of questions for cognitive and brain atrophy assessments. Results: The panel of experts was able to identify recent studies, which demonstrated the correlation between BVL and future worsening of disability and cognition. The current evidence revealed that reduction of BVL could be achieved with different disease-modifying therapies (DMTs). BVL provided a better treatment and monitoring strategy when it is combined to the composite measures of "no evidence of disease activity" (NEDA). The panel recommended a set of cognitive assessment tools and MRI methods and software applications that may help in capturing and measuring the underlying MS pathology with high degree of specificity. Conclusion: BVL was considered to be a useful measurement to longitudinally assess disease progression and cognitive function in patients with MS. Brain atrophy measurement was recommended to be incorporated into the concept of NEDA. Consequently, a consensus recommendation was reached in anticipation for implementation of the use of cognitive assessment and brain atrophy measurements on a regional level.

Original languageEnglish
Article number240
JournalBMC Neurology
Volume16
Issue number1
DOIs
Publication statusPublished - Nov 24 2016

Fingerprint

Multiple Sclerosis
Atrophy
Consensus
Outcome Assessment (Health Care)
Brain
Cognition
Politics
Autoimmune Diseases
Disease Progression
Chronic Disease
Software
Pathology
Therapeutics

Keywords

  • Brain atrophy
  • Cognitive impairment
  • Consensus
  • Disability progression
  • Middle East
  • Multiple sclerosis
  • NEDA

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Alroughani, R., Deleu, D., El Salem, K., Al-Hashel, J., Alexander, K. J., Abdelrazek, M. A., ... Rovira, À. (2016). A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurology, 16(1), [240]. https://doi.org/10.1186/s12883-016-0762-5

A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. / Alroughani, Raed; Deleu, Dirk; El Salem, Khalid; Al-Hashel, Jasem; Alexander, K. John; Abdelrazek, Mohamed Assem; Aljishi, Adel; Alkhaboori, Jaber; Al Azri, Faisal; Al Zadjali, Nahida; Hbahbih, Majed; Sokrab, Tag Eldin; Said, Mohamed; Rovira, Àlex.

In: BMC Neurology, Vol. 16, No. 1, 240, 24.11.2016.

Research output: Contribution to journalArticle

Alroughani, R, Deleu, D, El Salem, K, Al-Hashel, J, Alexander, KJ, Abdelrazek, MA, Aljishi, A, Alkhaboori, J, Al Azri, F, Al Zadjali, N, Hbahbih, M, Sokrab, TE, Said, M & Rovira, À 2016, 'A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis', BMC Neurology, vol. 16, no. 1, 240. https://doi.org/10.1186/s12883-016-0762-5
Alroughani R, Deleu D, El Salem K, Al-Hashel J, Alexander KJ, Abdelrazek MA et al. A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurology. 2016 Nov 24;16(1). 240. https://doi.org/10.1186/s12883-016-0762-5
Alroughani, Raed ; Deleu, Dirk ; El Salem, Khalid ; Al-Hashel, Jasem ; Alexander, K. John ; Abdelrazek, Mohamed Assem ; Aljishi, Adel ; Alkhaboori, Jaber ; Al Azri, Faisal ; Al Zadjali, Nahida ; Hbahbih, Majed ; Sokrab, Tag Eldin ; Said, Mohamed ; Rovira, Àlex. / A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. In: BMC Neurology. 2016 ; Vol. 16, No. 1.
@article{e079e01209cb4a008dd2dcdc906f03c5,
title = "A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis",
abstract = "Background: Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course of the disease at a rate greater than the general population. Brain volume loss (BVL) is associated with disability progression and cognitive impairment in patients with MS; hence its value as a potential target in monitoring and treating MS is discussed. Methods: A group of MS neurologists and neuro-radiologists reviewed the current literature on brain atrophy and discussed the challenges in assessing and implementing brain atrophy measurements in clinical practice. The panel used a voting system to reach a consensus and the votes were counted for the proposed set of questions for cognitive and brain atrophy assessments. Results: The panel of experts was able to identify recent studies, which demonstrated the correlation between BVL and future worsening of disability and cognition. The current evidence revealed that reduction of BVL could be achieved with different disease-modifying therapies (DMTs). BVL provided a better treatment and monitoring strategy when it is combined to the composite measures of {"}no evidence of disease activity{"} (NEDA). The panel recommended a set of cognitive assessment tools and MRI methods and software applications that may help in capturing and measuring the underlying MS pathology with high degree of specificity. Conclusion: BVL was considered to be a useful measurement to longitudinally assess disease progression and cognitive function in patients with MS. Brain atrophy measurement was recommended to be incorporated into the concept of NEDA. Consequently, a consensus recommendation was reached in anticipation for implementation of the use of cognitive assessment and brain atrophy measurements on a regional level.",
keywords = "Brain atrophy, Cognitive impairment, Consensus, Disability progression, Middle East, Multiple sclerosis, NEDA",
author = "Raed Alroughani and Dirk Deleu and {El Salem}, Khalid and Jasem Al-Hashel and Alexander, {K. John} and Abdelrazek, {Mohamed Assem} and Adel Aljishi and Jaber Alkhaboori and {Al Azri}, Faisal and {Al Zadjali}, Nahida and Majed Hbahbih and Sokrab, {Tag Eldin} and Mohamed Said and {\`A}lex Rovira",
year = "2016",
month = "11",
day = "24",
doi = "10.1186/s12883-016-0762-5",
language = "English",
volume = "16",
journal = "BMC Neurology",
issn = "1471-2377",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis

AU - Alroughani, Raed

AU - Deleu, Dirk

AU - El Salem, Khalid

AU - Al-Hashel, Jasem

AU - Alexander, K. John

AU - Abdelrazek, Mohamed Assem

AU - Aljishi, Adel

AU - Alkhaboori, Jaber

AU - Al Azri, Faisal

AU - Al Zadjali, Nahida

AU - Hbahbih, Majed

AU - Sokrab, Tag Eldin

AU - Said, Mohamed

AU - Rovira, Àlex

PY - 2016/11/24

Y1 - 2016/11/24

N2 - Background: Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course of the disease at a rate greater than the general population. Brain volume loss (BVL) is associated with disability progression and cognitive impairment in patients with MS; hence its value as a potential target in monitoring and treating MS is discussed. Methods: A group of MS neurologists and neuro-radiologists reviewed the current literature on brain atrophy and discussed the challenges in assessing and implementing brain atrophy measurements in clinical practice. The panel used a voting system to reach a consensus and the votes were counted for the proposed set of questions for cognitive and brain atrophy assessments. Results: The panel of experts was able to identify recent studies, which demonstrated the correlation between BVL and future worsening of disability and cognition. The current evidence revealed that reduction of BVL could be achieved with different disease-modifying therapies (DMTs). BVL provided a better treatment and monitoring strategy when it is combined to the composite measures of "no evidence of disease activity" (NEDA). The panel recommended a set of cognitive assessment tools and MRI methods and software applications that may help in capturing and measuring the underlying MS pathology with high degree of specificity. Conclusion: BVL was considered to be a useful measurement to longitudinally assess disease progression and cognitive function in patients with MS. Brain atrophy measurement was recommended to be incorporated into the concept of NEDA. Consequently, a consensus recommendation was reached in anticipation for implementation of the use of cognitive assessment and brain atrophy measurements on a regional level.

AB - Background: Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course of the disease at a rate greater than the general population. Brain volume loss (BVL) is associated with disability progression and cognitive impairment in patients with MS; hence its value as a potential target in monitoring and treating MS is discussed. Methods: A group of MS neurologists and neuro-radiologists reviewed the current literature on brain atrophy and discussed the challenges in assessing and implementing brain atrophy measurements in clinical practice. The panel used a voting system to reach a consensus and the votes were counted for the proposed set of questions for cognitive and brain atrophy assessments. Results: The panel of experts was able to identify recent studies, which demonstrated the correlation between BVL and future worsening of disability and cognition. The current evidence revealed that reduction of BVL could be achieved with different disease-modifying therapies (DMTs). BVL provided a better treatment and monitoring strategy when it is combined to the composite measures of "no evidence of disease activity" (NEDA). The panel recommended a set of cognitive assessment tools and MRI methods and software applications that may help in capturing and measuring the underlying MS pathology with high degree of specificity. Conclusion: BVL was considered to be a useful measurement to longitudinally assess disease progression and cognitive function in patients with MS. Brain atrophy measurement was recommended to be incorporated into the concept of NEDA. Consequently, a consensus recommendation was reached in anticipation for implementation of the use of cognitive assessment and brain atrophy measurements on a regional level.

KW - Brain atrophy

KW - Cognitive impairment

KW - Consensus

KW - Disability progression

KW - Middle East

KW - Multiple sclerosis

KW - NEDA

UR - http://www.scopus.com/inward/record.url?scp=84997169451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997169451&partnerID=8YFLogxK

U2 - 10.1186/s12883-016-0762-5

DO - 10.1186/s12883-016-0762-5

M3 - Article

C2 - 27881095

AN - SCOPUS:84997169451

VL - 16

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

IS - 1

M1 - 240

ER -